Healthcare >> CEO Interviews >> November 14, 2011
Vipin K. Garg, Ph.D., has served as President and Chief Executive Officer of Tranzyme, Inc., since September 2000 and as one of Tranzyme's Directors since October 2000. Prior to joining Tranzyme, he served as Chief Operating Officer of Apex Bioscience, Inc. - now Curacyte AG of Munich, Germany - where he was responsible for establishing a major strategic alliance with a Japanese pharmaceutical company and advancing the company's lead product into Phase II clinical development. Earlier, he was Vice President of Product Development and Manufacturing at DNX, Inc., and held management positions at Sunovion Pharmaceuticals Inc. - formerly known as Sepracor Inc., acquired by Dainippon Sumitomo Pharma Co, Ltd. - and Bio-Response Inc. - acquired by Baxter International Inc. Profile
TWST: Please describe Tranzyme.
Dr. Garg: Tranzyme Pharma is a late-stage biotechnology company focused on developing novel therapeutics for upper GI motility disorders. There are a number of
